Business Wire

Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Share

Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma. Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020.

This 12-week biomarker study is planned to randomize approximately 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary outcome measure of this randomized, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12.

“We estimate that there are more than two million moderate-to-severe eosinophilic asthma patients in the U.S. and are excited about further characterizing the clinical profile of oral dexpramipexole in this difficult-to-control disease,” said Michael E. Bozik, M.D., President and CEO of Knopp Biosciences.

Eosinophils are white-blood cells that play a central role in a number of debilitating diseases, including asthma, hypereosinophilic syndrome (HES), eosinophilic gastroenteritis, and atopic dermatitis. Knopp has previously reported the highly significant eosinophil-lowering effects of oral dexpramipexole including positive Phase 2 clinical trial results in HES .

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy and other CNS hyperexcitability disorders. Please visit www.knoppbio.com

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

James Heins
james.heins@icrinc.com
203-682-8251

Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Australian Government and Rimini Street Establish Whole-of-Government Agreement20.2.2020 02:00:00 EETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has established a new whole-of-government volume sourcing agreement with the Australian Government, which has the potential to generate significant savings on enterprise software support for government. The agreement is part of the government’s agenda to transform ICT procurement to make it simpler, clearer and faster for agencies and industry to transact services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219005895/en/ Australian Government and Rimini Street Establish Whole-of-Government Agreement (Graphic: Business Wire) Chief executive officer of the Australian Government’s Digital Transformation Agency, Mr. Randall Brugeaud, said the agreement with Rimini Street will make it easier and mor

BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes19.2.2020 20:00:00 EETPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization. In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management. This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration"). Ryan Sysko, President and CEO of Amalgam Rx, Inc, said:

H.I.G. Capital Acquires Vernacare19.2.2020 19:28:00 EETPress release

H.I.G. Capital, a leading global alternative asset manager with over $35 billion of equity capital under management, announced today that one of its affiliates has acquired Vernacare Limited (“Vernacare”), a leading international healthcare products specialist. Terms of the transaction were not disclosed. Established in 1964, Vernacare is an industry-leading manufacturer of infection control systems. It has pioneered single-use toileting systems globally, offering patients hygienic care and provides healthcare institutions with efficient, cost effective and environmentally sound toileting and bathing solutions. With sales in over 60 countries, the business employs over 250 people across its UK headquarters in Chorley, its manufacturing plant in Bolton and its Canadian base in Toronto. James Mitchell, Principal at H.I.G. Capital, commented on the transaction: “Vernacare is a growing industry leader in the manufacture of products that contain and dispose of infectious waste – critical sy

250 Firms Select the Moody’s Analytics CreditLens™ Solution19.2.2020 18:55:00 EETPress release

Moody’s Analytics, a leading provider of financial intelligence, announced today that more than 250 institutions globally selected the CreditLens credit lifecycle management solution, less than a year after reaching the 100-client threshold. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. It applies artificial intelligence and machine learning to facilitate process automation and help clients improve efficiency, reduce errors, and streamline workflows. The solution recently received a SOC 2 attestation report confirming its adherence to the American Institute of Certified Public Accountants’ security and availability controls standards. In 2019, Professional Bank became one of the first community banks in the US to automate its business loan applications. They accomplished this with the help of the CreditLens platform and other Moody’s Analytics tools

The Taulia Working Capital Summit Jets Into Johannesburg, Alongside Partners Greensill and Intellection19.2.2020 18:05:00 EETPress release

After two successful stints in San Francisco and Chicago, Taulia’s Working Capital Summit is set to launch in Johannesburg, South Africa for the very first time on March 11, 2020. The Working Capital Summit, hosted by The Money Show’s Bruce Whitfield will bring together some of the best and brightest minds in the financial technology business to discuss the latest in working capital finance solutions. The Working Capital Summit will provide a forum for key business minds to showcase their expert-leading industry knowledge, network with event-goers and discover unique ways to apply this knowledge to their own businesses. A recent Working Capital Index study conducted by JP Morgan found a staggering $460bn of working capital is confined across the supply chains of the S&P 1500 companies, which highlights an incredible opportunity for businesses to unlock trapped cash and propel their business’s growth through technology and innovation solutions. “Optimizing working capital and cash flow

Bioauxilium Introduces THUNDER™, a New Generation of TR‑FRET Cell Signaling Assay Kits19.2.2020 17:44:00 EETPress release

Bioauxilium Research Inc., a Canadian biotech specialized in the development and manufacturing of world-class time-resolved Förster resonance energy transfer (TR‑FRET) assay kits, announced today the launch of its proprietary no-wash THUNDER™ TR‑FRET cellular platform with the introduction of 68 new cell signaling assay kits. These top-quality, fully validated yet affordable cell-based kinase kits were designed to enable the simple, rapid and sensitive semi-quantitative detection of specific intracellular phosphorylated and/or total proteins in cell lysates. The ready-to-use THUNDER™ Cell Signaling Assay Kits are based on the higher specificity sandwich immunoassay format. However, in contrast to both conventional and improved ELISAs, they use a no-wash protocol with only one reagent addition and incubation step. This streamlined protocol dramatically decreases hands-on time and assay variability and is easily amenable to automation for high-throughput screening (HTS). The assays can b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom